CHUGAI PHARMACEUTICAL CO.,LTD.｜INNOVATION BEYOND IMAGINATION

Oct 30, 2017 "CEO Meeting" was held for the media.
Apr 3, 2017 Beware of Solicitations, "Phishing" e-mails, and SNS that Fraudulently Use the Name of Chugai Pharmaceutical

News Releases
What's New

Aug 03: For Media ＆ IRR&D
Anti-CD20 Monoclonal Antibody “RITUXAN^®,”
Application for Approval of Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
Jul 26: For Media ＆ IRCorporateR&D
Announcement of Business Expansion of
Chugai Pharmabody Research Pte. Ltd., Chugai’s Research Subsidiary
Jul 26: For Media ＆ IRCorporate
Organizational and Personnel Changes
Jul 26: For Media ＆ IRCorporate
Chugai Enters into Comprehensive Partnership Agreement with Preferred Networks
Jul 26: For Media ＆ IRCorporate
Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APls

More

Aug 03: Established ESG information site “ESG at Chugai”
Jul 30: Webcast of Investor Conference on FY2018 2Q Financial Results
Jul 27: Posted Corporate Governance Reports
Jul 27: Investor Conference on FY2018 2Q Financial Results
Jul 26: Financial Results for Second Quarter of Fiscal Year 2018 (January - June, 2018)

Share Price

TSE Code 4519

Share Graph

Video Introduction of CHUGAI

Videos & Advertisements

Back to top

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Share Price

Message from the CEO

R&D

Development
Pipeline

CSR

Recruit

Video Introduction of CHUGAI

Share Price

Message from the CEO

R&D

DevelopmentPipeline

CSR

Recruit

Video Introduction of CHUGAI

Development
Pipeline